1,826
Views
0
CrossRef citations to date
0
Altmetric
Editorial

New Strategies for Cancer management: How Can Temozolomide Carrier Modifications Improve Its delivery?

, , &
Pages 475-477 | Received 31 Jan 2017, Accepted 14 Feb 2017, Published online: 21 Jun 2017

References

  • Fang C Wang K Stephen ZR et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl. Mater. Interfaces7, 6674–6682 (2015).
  • Catalano M D'Alessandro G Lepore F et al. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol. Oncol.9, 1612–1625 (2015).
  • Chong DQ Toh XY Ho IA et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer15, 255 (2015).
  • Brem S Tyler B Li K et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother. Pharmacol.60, 643–650 (2007).
  • Tian XH Lin XN Wei F et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomedicine6, 445–452 (2011).
  • Jain A Chasoo G Singh SK et al. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J. Microencapsul.28, 21–28 (2011).
  • Irani M Mir Mohamad Sadeghi G Haririan I . A novel biocompatible drug delivery system of chitosan/temozolomide nanoparticles loaded PCL-PU nanofibers for sustained delivery of temozolomide. Int. J. Biol. Macromol.97, 744–751 (2017).
  • Fan L Yang Q Tan J et al. Dual loading miR-218 mimics and temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted anti-tumor drug delivery system with sequential release functions. J. Exp. Clin. Cancer Res.34, 106 (2015).
  • Di Martino A Sedlarik V . Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int. J. Pharm.474, 134–145 (2014).
  • Huang G Zhang N Bi X et al. Solid lipid nanoparticles of temozolomide: potential reduction of cardiac and nephric toxicity. Int. J. Pharm.355, 314–320 (2008).
  • Song S Mao G Du J et al. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv.23, 1404–1408 (2016).
  • Wu M Fan Y Lv S et al. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv.23, 2720–2725 (2016).
  • Ananta JS Paulmurugan R Massoud TF . Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol. Res.38, 51–59 (2016).
  • Lee CY Ooi IH . Preparation of temozolomide-loaded nanoparticles for glioblastoma multiforme targeting-ideal versus reality. Pharmaceuticals (Basel)9, 54 (2016).
  • Patil R Portilla-Arias J Ding H et al. Temozolomide delivery to tumor cells by a multifunctional nano-vehicle based on poly(beta-L-malic acid). Pharm. Res.27, 2317–2329 (2010).
  • Cho HY Wang W Jhaveri N et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer. Ther.13, 2004–2017 (2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.